Brief: Vicore Buys Novel AT2R Agonists And Decides On Issue In Kind

Vicore Pharma Holding AB

02/11/2020 07:03

Nov 2 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE STRENGTHENS ITS PIPELINE WITH THE ACQUISITION OF
NOVEL
AT2R AGONISTS AND DECIDES ON AN ISSUE IN KIND OF 142,054 SHARES
    * ACQUISITION OF A SERIES OF INTELLECTUAL PROPERTY RIGHTS
(IPR) AS
PART OF DEVELOPMENT OF NOVEL ANGIOTENSIN II TYPE 2 RECEPTOR
(AT2R) AGONISTS
    * BOARD HAS TODAY DECIDED ON A SHARE ISSUE OF CORRESPONDING
NUMBER
OF SHARES TO BE SUBSCRIBED FOR BY HALACORE
    * AS COMPENSATION FOR ACQUISITION, HALACORE WILL RECEIVE A
ONE-TIME PAYMENT OF 6 MSEK, SPLIT BETWEEN APPROXIMATELY 3 MSEK
IN CASH AND 142,054 SHARES IN VICORE CORRESPONDING TO
APPROXIMATELY 3 MSEK
    * NUMBER OF SHARES PAYABLE TO HALACORE IS BASED ON A SHARE
PRICE
OF APPROXIMATELY 21,1 SEK PER SHARE

Source text for Eikon:  ID:nWkr9SlQxd 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785110;))